Top Markets
Coin of the day
Agile Therapeutics, Inc. Agile Therapeutics, Inc.

Agile Therapeutics, Inc.

AGRX
주식 순위 #38231
Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated... Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.
주가
$1.51
마지막 동기화: 2024-08-26
시가총액
$1.12M
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Agile Therapeutics, Inc. (AGRX)

카테고리

Agile Therapeutics, Inc. (AGRX)의 수익
Jun 2024 기준 수익 TTM: $-15.86M
Agile Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-15.86M입니다. 2022년에 회사는 $-30.09M의 수익을 올렸으며 이는 2021년의 수익 $-74.89M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Agile Therapeutics, Inc.의 수익 기록 (2012 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-15.86M 9.62%
2023 $-14.47M -51.92%
2022 $-30.09M -59.83%
2021 $-74.89M 44.44%
2020 $-51.85M 178.69%
2019 $-18.61M -8.15%
2018 $-20.26M -28.43%
2017 $-28.30M -11.04%
2016 $-31.82M -12.37%
2015 $-36.31M 84.02%
2014 $-19.73M 37.77%
2013 $-14.32M -38.43%
2012 $-23.26M 0.00%
유사 기업 또는 경쟁사의 수익